Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference
09 sept. 2024 08h30 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily...
Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
04 sept. 2024 08h15 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily...
Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
12 août 2024 16h01 HE
|
Journey Medical Corporation
New Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of November 4, 2024 Total revenues for the second quarter ended June 30, 2024 were $14.9 million, a 14% increase...
Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024
06 août 2024 16h01 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses...
Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors
11 juil. 2024 16h05 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and...
Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
15 mai 2024 16h01 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses...
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
13 mai 2024 16h01 HE
|
Journey Medical Corporation
New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a 7%...
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024
07 mai 2024 08h30 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the...
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer
01 mai 2024 16h01 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses...
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
25 avr. 2024 08h30 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., April 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily...